Celator Pharmaceuticals Inc (NASDAQ:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, …
Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) closed yesterday up almost 24% after the company reported that CPX-351, a drug aimed to treat Acute Myeloid Leukemia …
In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …
